Overview
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Status:
Recruiting
Recruiting
Trial end date:
2024-05-01
2024-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT)Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Glaukos CorporationTreatments:
Ophthalmic Solutions
Timolol
Travoprost
Criteria
Inclusion Criteria:- Diagnosed with open-angle glaucoma or ocular hypertension
- C/D ratio ≤ 0.8
- Zero to two preoperative ocular hypotensive medications
Exclusion Criteria:
- Active corneal inflammation or edema
- Retinal disorders not associated with glaucoma